10th International Congress on Genitourinary Malignancies

Venue: TBA

Location: Washington, Washington DC, United States

Event Date/Time: Jul 16, 2010 End Date/Time: Jul 17, 2010
Registration Date: Jul 15, 2010
Early Registration Date: Apr 30, 2010
Report as Spam


A comprehensive review of current therapeutic strategies for the treatment of all stages of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and new therapeutic agents. Interactive panel discussions and case-based vignettes will provide practical clinical context for the interpretation of the presented trial data. Faculty recommendations and an interactive tumor board discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to apply the latest advances in the treatment of genitourinary malignancies to their daily practice and discuss future directions in research and clinical trials.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists and urologists interested in the treatment of patients with genitourinary malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of genitourinary malignancies are also invited to attend.


Additional Information

Learning Objectives At the conclusion of this congress, you should be able to: Differentiate patient prognostic groups based on pretreatment risk features in renal cell carcinoma Incorporate current standards into the surgical and clinical management of patients with localized renal cell carcinoma Select appropriate targeted therapies for the treatment of advanced renal cell carcinoma based on patient characteristics and prior therapy Evaluate the efficacy and safety of different sequential and combination therapy options for advanced renal cell carcinoma Discuss emerging therapies and therapeutic strategies in the refractory/resistant setting for renal cell carcinoma Monitor and provide supportive therapy for treatment-related toxicities in patients with advanced renal cell carcinoma Incorporate current evidence-supported treatment, including surgical and systemic therapy options, into the management of all stages of bladder cancer Identify genetic markers associated with prognosis in prostate cancer Appraise the risk-benefit profile of chemoprevention strategies for individual patients with prostate cancer Integrate updated concepts for multimodality treatment, including surgery, radiation therapy, and hormonal therapy, into the management of patients with localized and high-risk prostate cancer Apply appropriate chemotherapy to the management of castrate-resistant prostate cancer Evaluate the role of novel immunotherapies and targeted agents in the treatment of castrate-resistant prostate cancer Assess the genesis of therapy resistance in prostate cancer and renal cell carcinoma Assess the role of bone-targeted therapies in the management of patients with advanced prostate cancer